MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala, DuoPlavin, Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E

Overview

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) . Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others . Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures . The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound). Other indications ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) . Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction . For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) . For the prevention of thromboembolism after hip replacement surgery . For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) . Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site . Important note regarding use of the extended-release formulation In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions

  • Acute Coronary Syndrome (ACS)
  • Anxiety
  • Atherothrombotic cerebral infarction
  • Cardiovascular Disease (CVD)
  • Cardiovascular Events
  • Cardiovascular Mortality
  • Colorectal Adenomas
  • Colorectal Cancer
  • Common Cold
  • Coronary artery reocclusion
  • Death
  • Dyspeptic signs and symptoms
  • Fever
  • Flu caused by Influenza
  • Headache
  • Heterozygous Familial Hypercholesterolemia (HeFH)
  • Inflammation
  • Juvenile Idiopathic Arthritis (JIA)
  • Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
  • Menstrual Pain
  • Migraine
  • Morbidity
  • Mucocutaneous Lymph Node Syndrome
  • Muscle Contraction
  • Myalgia
  • Myocardial Infarction
  • Myocardial Infarction (MI), first occurrence
  • Neuropathic Pain
  • Pain
  • Pain caused by Common Cold
  • Pain caused by Rheumatism
  • Pericarditis
  • Polycythemia Vera (PV)
  • Pre-Eclampsia
  • Rheumatism
  • Rheumatoid Arthritis
  • Rhino Sinusitis
  • Severe Pain
  • Spondyloarthropathies
  • Stroke
  • Systemic Lupus Erythematosus
  • Tension Headache
  • Thromboembolism
  • Thrombosis
  • Toothache
  • Transient Ischemic Attack
  • Vascular Death
  • Venous Thromboembolism
  • Acute Inflammation
  • Articular inflammation
  • Atherothrombotic events
  • Death caused by Myocardial Infarction
  • Fever or influenza-like illness
  • Moderate Pain
  • Recurrent Ischemic Stroke

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/07/07
Not Applicable
Not yet recruiting
2025/06/27
N/A
Not yet recruiting
Shalamar Hospital
2025/05/20
Phase 3
Recruiting
The George Washington University Biostatistics Center
2025/05/01
Phase 3
Not yet recruiting
FANG HE
2025/04/20
Phase 2
Recruiting
2025/02/14
Phase 1
Not yet recruiting
2025/01/03
Phase 4
Not yet recruiting
2025/01/03
Phase 4
Not yet recruiting
Beijing Anzhen Hospital
2024/12/18
Phase 4
Recruiting
2024/12/09
Phase 4
Recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Physicians Total Care, Inc.
54868-2094
ORAL
325 mg in 1 1
8/29/2011
Cabinet Health P.B.C.
82725-1023
ORAL
250 mg in 1 1
1/31/2025
Dispensing Solutions, Inc.
66336-619
ORAL
325 mg in 1 1
9/1/2011
HF Acquisition Co LLC, DBA HealthFirst
51662-1494
ORAL
325 mg in 1 1
5/1/2025
ST. MARY'S MEDICAL PARK PHARMACY
60760-673
ORAL
81 mg in 1 1
3/3/2025
Aralez Pharmaceuticals Us Inc.
70347-081
ORAL
81 mg in 1 1
9/26/2016
Atland Pharmaceuticals, LLC
71993-307
ORAL
770 mg in 1 1
6/19/2023
Sun Pharmaceutical Industries, Inc.
47335-927
ORAL
25 mg in 1 1
1/18/2019
Micro Labs Limited
42571-274
ORAL
25 mg in 1 1
11/28/2022
Aidarex Pharmaceuticals LLC
33261-922
ORAL
325 mg in 1 1
12/26/2013

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Aspirin Chewable Tablets
国药准字H20217027
化学药品
片剂
4/7/2021
Aspirin Chewable Tablets
国药准字H20040222
化学药品
片剂
5/7/2020
Aspirin Tablets
国药准字H62020243
化学药品
片剂
4/10/2020
Aspirin Tablets
国药准字H64020046
化学药品
片剂
11/21/2019
Aspirin Tablets
国药准字H37022276
化学药品
片剂
6/15/2023
Aspirin Tablets
国药准字H42020508
化学药品
片剂
9/3/2020
Aspirin Tablets
国药准字H34020562
化学药品
片剂
5/12/2020
Aspirin Tablets
国药准字H12020914
化学药品
片剂
8/27/2020
Aspirin Tablets
国药准字H41023651
化学药品
片剂
5/6/2020
Aspirin Tablets
国药准字H53020322
化学药品
片剂
7/31/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
CASPRIN GASTRO-RESISTANT CAPSULES 100MG
N/A
N/A
N/A
12/9/2024

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath